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Effect of GNF-2 and Abl kinase Inhibitors (AKIs) on the 
proliferation and clonigenicity of Ba/F3 cells 
 
We tested the ability of Imatinib and Dasatinib to affect the growth of the parental Ba/F3 
cells grown in the presence of IL-3 (10 ng/ml). Cells were treated with increasing 
concentration of Imatinib and Dasatinib for 72 hrs. Percentage of growth inhibition was 
calculated relative to solvent-treated samples. Data shown in Figure S1 indicated that 
Imatinib at 5M had very little effect on growth of Ba/F3 cells; more than 90% of the cells 
were viable. In contrast, Dasatinib was more potent in inhibiting the growth of Ba/F3 cells.  
Presence of Dasatinib at 2.5 M caused a decrease in cell survival to 65%.  
Interestingly, Dasatinib at 50nM and Imatinib at 1M caused minimal proliferation 
inhibition, of less than 10%, and concentrations were selected to verify cooperation with 
GNF-2, in affecting proliferation and survivals of Ba/F3 cells.  
Data presented in figure S2 showed that Imatinib (1 M) and Dasatinib (50nM) failed to 
cooperate with GNF-2 in affecting proliferation of Ba/F3 cells. The calculated IC50 of cells 
treated with GNF-2, in the absence or presence of Imatinib and Dasatinib, was almost 
identical, of 30 +/- 0.2 M, indicating that no cooperation between GNF-2 and AKIs in 
controlling the proliferation of the parental Ba/F3 cells was observed. 
Next, the ability of GNF-2 to affect clonigenicity of Ba/F3 cells grown in the presence of IL-3 
(10ng/ml) was examined. Imatinib and Dasatinib at 1M exhibited minimal effect on 
clonigenicity of Ba/F3 cells. GNF-2 caused clonigenicity inhibition of Ba/F3, as shown in 
Figure S3. Moreover, presence of 1M of Imatinib and Dasatinib marginally affected the IC, 
arguing that no significant cooperation exists between GNF-2 and AKIs in inhibiting the 
proliferation and clonigenicity of the parental Ba/F3 cells.  
Figure S1: Effect of Imatinib and Dasatinib on the proliferation of Ba/F3 (Blue) and Ba/F3 
p185 Bcr-Abl (Red) cells. The cells supplemented with 10 ng/ml of IL-3, were grown for 72 
hrs in the presence of different Imatinib and Dasatinib concentrations. Cells were counted 
and percent of inhibition was calculated in relation to the solvent (0.5% DMSO) treated 
samples. Experiments were carried out in duplicates and repeated twice with comparable 
outcome. 
 
 
 
 
  
Figure S2:  Cooperation between GNF-2 with Imatinib and Dasatinib in regulating 
proliferation of Ba/F3 cells. Ba/F3 supplemented with 10 ng/ml of IL-3 were grown for 72 hrs 
in the presence of various GNF-2 concentration (0.1, 0.5, 2.5, 5, 25 and 125 M) alone or in 
combination with Imatinib (1 M) and Dasatinib (50 nM). After 72 hrs incubation, cells were 
counted and percent of inhibition was calculated in relation to the solvent (0.5% DMSO) 
treated samples. Experiments were carried out in duplicates and repeated twice with 
comparable outcome. 
 
 
 
  
Figure S3: Effect of GNF-2 and AKIs on the clonigenicity of Ba/F3 cells.  Ba/F3 cells grown on 
soft agar were treated with solvent (DMSO 0.5%; Un), Imatinib (1µM), Dasatinib (1µM), and 
GNF-2 (5µM-100 µM) alone or in the presence of either 1µM Imatinib or 1µM Dasatinib.  
Experiments were carried out in duplicates and repeated twice with comparable outcome. 
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